Denali Therapeutics Secures $275 Million Royalty Deal with Royalty Pharma for Hunter Syndrome Therapy
核心洞察
Denali Therapeutics and Royalty Pharma announced a $275 million synthetic royalty funding agreement based on future sales of tividenofusp alfa, an investigational enzyme replacement therapy for Hunter syndrome (搜索).
The therapy utilizes Denali's proprietary TransportVehicle platform to cross the blood-brain barrier (搜索) and is currently under FDA review for accelerated approval with a PDUFA target date of April 5, 2026.
Under the agreement, Royalty Pharma will pay $200 million at closing and an additional $75 million upon European approval, receiving a 9.25% royalty on worldwide net sales.
Denali Therapeutics Inc. and Royalty Pharma plc announced a $275 million synthetic royalty funding agreement on December 4, 2025, based on future net sales of tividenofusp alfa, Denali's lead investigational therapy for mucopolysaccharidosis type II (搜索) (MPS II (搜索)), commonly known as Hunter syndrome (搜索). The agreement represents a significant vote of confidence in the therapeutic potential of Denali's blood-brain barrier (搜索) crossing technology.
TransportVehicle Platform Enables Brain Penetration
Tividenofusp alfa is an enzyme replacement therapy enabled by Denali's proprietary TransportVehicle platform, designed to deliver therapeutics across the blood-brain barrier (搜索). A Biologics License Application (BLA) for accelerated approval is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of April 5, 2026.
"We are pleased to partner with Royalty Pharma, whose investment recognizes the value and potential of tividenofusp alfa for the Hunter community and supports our ability more broadly to realize the promise of the TransportVehicle platform," said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. "With these additional funds, we are well positioned to advance our development programs as we prepare for the launch of tividenofusp alfa, unlocking broad opportunities across serious diseases."
Addressing Unmet Medical Need in Hunter Syndrome
Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma, emphasized the therapeutic significance of the partnership. "We are delighted to partner with Denali and acquire a royalty on tividenofusp alfa, an innovative therapy that addresses a significant unmet need in the cognitive and physical manifestations of Hunter syndrome (搜索)," Legorreta said. "Denali's technology platform delivers therapeutics across the blood-brain barrier (搜索) and is a promising new approach to brain diseases. We are thrilled to establish a relationship with Denali and believe tividenofusp alfa is a potential practice-changing therapy that could transform the lives of patients with Hunter syndrome."
Financial Structure and Milestones
The transaction is contingent upon various closing conditions, including Denali achieving U.S. FDA accelerated approval of tividenofusp alfa. Upon closing, Royalty Pharma will make an initial payment of $200 million, with an additional $75 million payment due upon achieving European Medicines Agency (EMA) approval by December 31, 2029.
In exchange for the funding, Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa. The royalty payments will terminate upon reaching a multiple of 3.0x of the total investment, or 2.5x if achieved by the first quarter of 2039.
Platform Technology with Broader Applications
Denali Therapeutics is positioning itself as a biotechnology company pioneering biotherapeutics designed to cross the blood-brain barrier (搜索) using its TransportVehicle platform. The company maintains a growing portfolio of therapeutic candidates across all stages of development, targeting neurodegenerative, lysosomal storage, and other serious diseases.
Royalty Pharma, founded in 1996, operates as the largest buyer of biopharmaceutical royalties and maintains a portfolio of royalties on more than 35 commercial products, including therapies from major pharmaceutical companies such as Vertex, GSK, Roche, Johnson & Johnson, Biogen, and others.